The role of covariates in estimating treatment effects and risk in long-term clinical trials

Statistics in Medicine

Volumn 21, Issue 19, 2002, Pages 2899-2908

  Ford, Ian ^a   Norrie, John ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

Exponential regression; Parameter estimation; Proportional hazards model; Risk modelling

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PRAVASTATIN;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; HUMAN; LINEAR SYSTEM; LONG TERM CARE; PREDICTION; PUBLICATION; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; STATISTICAL MODEL; STATISTICS; TREATMENT OUTCOME; VALIDATION PROCESS;

HUMANS; LONGITUDINAL STUDIES; MODELS, BIOLOGICAL; MODELS, STATISTICAL; RANDOMIZED CONTROLLED TRIALS; RISK FACTORS; TREATMENT OUTCOME;

EID: 0037108044     PISSN: 02776715     EISSN: None     Source Type: Journal    
DOI: 10.1002/sim.1294     Document Type: Article

References (42)

1. Ford I, Norrie J, Ahmadi S. Model inconsistency, illustrated by the Cox proportional hazards model. Statistics in Medicine 1995; 14:735-746.
2. Robinson LD, Jewell NP. Some surprising results about covariate adjustment in logistic regression models. International Statistical Review 1991; 59:227-240.
3. Cox DR. Regression models and life tables (with discussion). Journal of the Royal Statistical Society, Series B 1972; 34:187-220.
4. Cox DR. Partial likelihood. Biometrika 1975; 63:269-276.
5. Fleming TR, Lin DY. Survival analysis in clinical trials: past developments and future directions. Biometrics 2000; 56:971-983.
6. Oakes D. Bivariate survival models induced by frailties. Journal of the American Statistical Association 1989; 84:487-493.
7. Pickles A, Crouchley R. Generalisations and applications of frailty models for survival and event data. Statistical Methods in Medical Research 1994; 3:263-278.
8. Crowder M. A distributional model for repeated failure time measurements. Journal of the Royal Statistical Society, Series B 1985; 47:447-452.
9. Clayton D, Cuzick J. Multivariate generalisations of the proportional hazards model (with discussion). Journal of the Royal Statistical Society, Series A 1985; 148:82-117.
10. Crowder M. A multivariate distribution with Weibull connections. Journal of the Royal Statistical Society, Series B 1989; 51:93-107.
11. Hougaard P. Survival models for heterogenous populations derived from stable distributions. Biometrika 1986; 73:387-396 (correction 75; 395).
12. Oakes D. Semiparametric inference, in a model for association in bivariate survival data. Biometrika 1986; 73:353-361.
13. Gail MH, Wieand S, Piantadosi S. Biased estimates of treatment effect in randomised experiments with non-linear regressions and omitted covariates. Biometrika 1984; 71:431-444.
14. Solomon PJ. Effect of misspecification of regression models in the analysis of survival data. Biometrika 1984; 71:291-298 (amendment 1986; 73:245).
15. Struthers CA, Kalbfleisch JD. Misspecified proportional hazards models. Biometrika 1986; 73:363-369.
16. Anderson GL, Fleming TR. Model misspecification in proportional hazards regression. Biometrika 1995; 82: 527-541.
17. Lagakos SW, Schoenfeld DA. Properties of proportional hazards score tests under misspecified regression models. Biometrics 1984; 40:1037-1048.
18. Morgan TM. Omitting covariates from the proportional hazards model. Biometrics 1986; 42:993-995.
19. Chastang C, Byar D, Piantadosi S. A quantitative study on the bias in estimating the treatment effect caused by omitting a balanced covariate in survival models. Statistics in Medicine 1988; 7:1243-1255.
20. Bretagnolle J, Huber-Carol C. Effects of omitting covariates in Cox's model for survival data. Scandinavian Journal of Statistics 1988; 15:125-138.
21. Schmoor C, Schumacher M. Effects of covariate omission and categorisation when analysing randomised trials with the Cox model. Statistics in Medicine 1997; 16:225-237.
22. Aalen OO. Effects of frailty in survival analyses. Statistical Methods in Medical Research 1994; 3:227-243.
23. Henderson R, Oman P. Effect of frailty on marginal regression estimates in survival analysis. Journal of the Royal Statistical Society, Series B 1999; 61:367-379.
24. Hastie T, Tibsharini R. Exploring the nature of covariate effects in the proportional hazards model. Biometrics 1990; 46:1005-1016.
25. Hauck WW, Anderson S, Marcus SM. Should we adjust for covariates in non-linear regression analyses of randomised trials? Controlled Clinical Trials 1998; 19:249-256.
26. The West of Scotland Coronary Prevention Study Group. A coronary primary prevention study of Scottish men aged 45-64 years: trial design. Journal of Clinical Epidemiology 1992; 45:849-860.
27. West of Scotland Coronary Prevention Study. Screening experience and baseline characteristics in WOSCOPS. American Journal of Cardiology 1995; 76:485-491.
28. Shepherd J, Cobbe SM, Ford I, Isles C, Lorimer AR, Macfarlane PW, McKillop JH, Packard CJ for the West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. New England Journal of Medicine 1995; 333:1301-1307.
29. Feely T, McGettigan P, Kelly A. Growth in the use of statins after trials is not targeted to the most appropriate patients. Clinical Pharmacology and Therapeutics 2000; 67:438-441.
30. Primatesta P, Poulter NR. Lipid concentrations and the use of lipid lowering drugs: evidence from a national cross sectional survey. British Medical Journal 2000; 321:1322-1325.
31. NHS Centre for Reviews and Dissemination; University of York. Getting evidence into practice. Eftective Health Care 1999; 5:1-16.
32. Isles CG, Ritchie LD, Murchie P, Norrie J. Risk assessment in primary prevention of coronary heart disease: randomised comparison of three scoring methods. British Medical Journal 2000; 320:690-691.
33. Durrington P, Prais H, Bhatnager D, France M, Crowley V, Khan J, Morgan J. Indications for cholesterol lowering medications: comparisons of risk assessment methods. Lancet 1999; 353:278-281.
34. Working party of the British Cardiac Society, British Hyperlipidaemia Association, and British Hypertension Society. Joint British recommendations on prevention of coronary heart disease in clinical practice. Heart 1998; 80(suppl. 2):S1-S29.
35. Wood DA, De Backer G, Faergeman O, Graham I, Mancia C, Pyörälä K. Prevention of coronary heart disease in clinical practice. Recommendation of the second joint task force of the European Society for Cardiology, European Artherosclerosis Society and European Society of Hypertension. European Heart Journal 1998; 19:1434-1503.
36. The West of Scotland Coronary Prevention Study. Identification of high-risk groups and comparison with other cardiovascular intervention trials. Lancet 1996; 348:1339-1342.
37. The West of Scotland Coronary Prevention Study. Baseline risk factors and their association with outcome in WOSCOPS. American Journal of Cardiology 1997; 79:756-762.
38. Caro J, Klittich W, McGuire A, Ford I, Norrie J, Pettitt D, McMurray J, Shepherd J, for the West of Scotland Study Group. The West of Scotland Coronary Prevention Study: economic benefit analysis of primary prevention with pravastatin. British Medical Journal 1997; 315: 1577-1582.
39. International Conference on Harmonisation (ICH). E9: Statistical Principles for Clinical Trials. The European Agency for the Evaluation of Medicinal Products: London, 1989.
40. Raab GM, Day S, Sales J. How to select covariates to include in the analysis of a clinical trial. Controlled Clinical Trials 2000; 21:330-342.
41. Assmann SF, Pocock SJ, Enos LE, Kasten LE. Subgroup analysis and other (mis)uses of baseline data in clinical trials. Lancet 2000; 355:1064-1069.
42. Follmann DA, Proschan MA. A multivariate test of interaction for use in clinical trials. Biometrics 1999; 55:1151-1155.